The Money Map folks have decided that it’s time to go “all in” on cannabis, and for them that means starting a new investment research business that they call the National Institute for Cannabis Investors, and selling memberships in that group by teasing their favorite “special reports” on some appealing marijuana stocks that they’ll give […]
Entry level research service that promises a new “Cannabis Investment Package” each month, recommending different stocks in the sector.
This article was originally published as part of the Friday File on August 10, 2018. It has not been updated or revised, though the stock teased is still at roughly the same price and no major news has hit since then. We’re breaking the Friday File up into two parts today — starting with this […]
Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]
This Friday File article was originally released to the Irregulars on June 16, we have now opened it up for anyone to read in hopes of answering some questions that continue to roll in about the latest Biotech Insider Alert ads. The text below has not been updated or revised, though I and other readers […]
I know quite a few folks got to chatting about Bellicum (BLCM) following Ernie Tremblay’s overly heated pitch for the stock last week, covered in the Friday File a week ago… and, well, things so far are going as they often do: Overhype the ad, overpromise some dramatic results from a presentation that’s really much […]
Ernie Tremblay’s teaser pitches about imminent FDA decisions or other biotech catalysts always get a lot of attention — not necessarily because he’s always right (ARLZ did get approval for their drug, but the stock is actually down… EARS did not “double by August 31” because the trial he was teasing failed on efficacy), but […]
Another month, another big pitch about a biotech stock with a great “P-Value Indicator” from Ernie Tremblay, all in an ad for his Biotech Insider Alert. Should we pay attention? Well, we can hardly avoid noticing it — we’re being battered about the head and neck with the constant email fusillade from Tremblay’s publisher and […]
Ernie Tremblay is the name behind the Biotech Insider Alert newsletter ($1,950/year) at Money Map Press, and his claim is that he has a “P-Value” formula that helps him to identify biotech stocks that are about to release good data that can send their shares soaring. I’m not going to get into the actual “formula” […]
This ad first showed up in our inboxes under the “end surgery forever” headline in late January, and the following article first appeaered on January 26. We have not gone through and updated the article, though the basic pitch is just about the same in the new version of the ad today as it was […]
Golly, most people who might subscribe to investment newsletters are baby boomers. And most of that generation is just a few years past their midlife crisis… so you can be pretty sure that a “silent epidemic” will get them to read your ad, yes? Apparently so, if the questions rolling in to Gumshoe HQ over […]
Heads up: I made a mistake on this one when it first went up on the site. We strive for at least a 99% accuracy rate in identifying teaser targets, and this is apparently my mistake for 2014. Thanks to several readers for alerting me to the fact that I moved too quickly in posting […]
I know a great many of the Irregulars have been interested in FDA dates recently, partly thanks to the community of biotech enthusiasts who have coalesced around the musings of our own Dr. KSS, so I thought I’d spin out a quick answer to you for a teaser pitch that’s been sent out quite breathlessly […]
Newsletter/trading service that aims to track important trading catalyst dates for biotech stocks, including FDA approvals and submissions and clinical trial data releases. Formerly called BioScience Millionaire.